arsenic trioxide has been researched along with Lymphoma, Large B-Cell, Diffuse in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chau, D; Kwong, YL; Tse, E; Yue, LM | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Gazin, C; Jin, XL; Li, XS; Ma, J; Naoe, T; Ni, JH; Shen, ZX; Shi, XG; Si, GY; Sun, GL; Tang, W; Wang, ZY; Xong, SM; Zhang, P; Zhang, TD; Zhong, HJ; Zhu, J | 1 |
2 other study(ies) available for arsenic trioxide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Humans; Lymphoma, Large B-Cell, Diffuse; Oncogene Proteins, Fusion | 2021 |
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Medicine, Chinese Traditional; Monocytes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1996 |